Every 8-K that Clorox Co Del (CLX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CLX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLX filings page.
The Clorox Company reported fourth-quarter and fiscal 2026 results marked by lower sales and earnings while integrating its GOJO acquisition and completing a major U.S. ERP transition. Q4 net sales decreased 2% to $1.95 billion, with organic sales down 13% as the company lapped elevated shipments ahead of last year’s ERP cutover. Q4 diluted EPS fell 50% to $1.34 and adjusted EPS declined 42% to $1.66, reflecting lower volume, a 520-basis-point gross-margin decline to 41.3%, and GOJO-related inventory step-up and integration costs.
For fiscal 2026, net sales declined 5% to $6.72 billion and organic sales fell 8%. Diluted EPS decreased 26% to $4.81, while adjusted EPS decreased 28% to $5.53, including an estimated 90-cent headwind from ERP-related shipment timing. Net cash provided by operations was $612 million, down from $981 million, primarily due to the Glad venture-termination payment, while adjusted free cash flow was $881 million. Clorox expects fiscal 2027 net sales to grow 13%–14%, including about 9.5 points from GOJO, and guides diluted EPS to $5.41–$5.71 and adjusted EPS to $5.70–$6.00, aided by lapping the ERP inventory drawdown.
The Clorox Company announced a streamlined operating structure and key leadership changes. Chris Hyder was appointed executive vice president and chief operating officer, effective June 17, 2026, consolidating leadership of all business units under a single executive to drive end-to-end execution.
In connection with his promotion, Hyder’s base salary will increase to $800,000, and his short-term incentive target will rise from 90% to 100% of salary. He will also receive $4,000,000 in restricted stock units on June 17, 2026, vesting after three years.
Nina Barton, previously executive vice president and group president – Care & Connection, was named executive vice president and chief growth & strategy officer, effective June 17, 2026, with responsibility for innovation, strategy, portfolio shaping and commercial functions. The company highlighted these changes as part of a simplified structure intended to improve execution and accelerate growth, while the board continues a comprehensive search for a new CEO.
The Clorox Company announced that Chair and CEO Linda Rendle has asked the board to begin a comprehensive CEO search as she plans to step down for health reasons. She will remain in her roles while the search is conducted and until a new CEO is appointed.
Rendle will then serve in an advisory position for a period to support business performance and a smooth leadership transition. An independent board committee, supported by an external executive search firm, will lead the process. Rendle and CFO Luc Bellet also plan to speak at the dbAccess Global Consumer Conference on June 3 in Paris.
The Clorox Company entered into an underwriting agreement for a registered public offering of new senior notes. The company sold $550,000,000 of 4.700% Senior Notes due 2031, $400,000,000 of 4.950% Senior Notes due 2033, and $550,000,000 of 5.250% Senior Notes due 2036. The offering closed on May 11, 2026, under an existing Indenture dated May 11, 2022, with U.S. Bank Trust Company, National Association, as trustee. Legal validity of the securities is supported by an opinion from Cleary Gottlieb Steen & Hamilton LLP.
The Clorox Company reported mixed third-quarter fiscal 2026 results. Net sales were $1.67 billion, essentially flat year over year, while organic sales decreased 1%. Gross margin fell 140 basis points to 43.2% as higher manufacturing and logistics costs and unfavorable mix more than offset cost savings.
Diluted EPS rose 3% to $1.54, and adjusted EPS grew 13% to $1.64, helped by cost savings, lower advertising and lower selling and administrative expenses. Year-to-date net cash provided by operations was $282 million, down 59% from $687 million, mainly due to a Glad joint venture termination payment.
The company completed its acquisition of GOJO Industries on April 1, adding the Purell brand and related health and hygiene products. Clorox cut its full-year 2026 outlook, now expecting net sales to decline about 6% and organic sales to decrease about 9%. Fiscal 2026 diluted EPS is projected between $4.78 and $4.98, a 24% to 27% decline, while adjusted EPS is guided to $5.45 to $5.65, down 27% to 29%, reflecting ERP-related shipment timing, GOJO integration costs and ongoing digital investments.
The Clorox Company completed its acquisition of GOJO Industries, makers of Purell, on April 1, 2026. Clorox purchased all issued and outstanding membership interests of GOJO under a membership interest purchase agreement with GOJO Industries Holdings and its shareholders. The acquired business will operate as Clorox Purell, led by President Carey Jaros, based in Akron, Ohio, with existing facilities remaining in Ashland, Cuyahoga Falls and Wooster, Ohio. Clorox describes the combination as expanding its health and hygiene portfolio and reinforcing its strategy to deliver comprehensive solutions for both consumers and institutional customers.
The Clorox Company entered into two new unsecured credit facilities totaling $2.25 billion to support its planned acquisition of GOJO Industries, maker of PURELL, and for general corporate purposes.
The first is a $1.0 billion 364-day revolving credit agreement available in U.S. dollars for general corporate use. Borrowings are available until March 5, 2027, and Clorox may convert outstanding amounts into a term loan maturing March 5, 2028. Pricing is based on either a base rate or Term SOFR plus a margin tied to Clorox’s senior unsecured credit rating, and a quarterly facility fee also varies with that rating.
The second is a $1.25 billion delayed draw term credit agreement available at the closing of the GOJO acquisition to finance part of the purchase price, pay related fees and expenses, and repay certain GOJO debt, with any remaining amounts available for general corporate purposes. Loans under this facility mature on March 5, 2027, and undrawn commitments terminate on the earliest of December 31, 2026, termination of the acquisition agreement, or closing of the acquisition without using this financing. Both agreements include customary covenants and events of default, with a consolidated interest coverage ratio as the sole financial covenant and mandatory reductions or prepayments from certain future debt or equity proceeds.
The Clorox Company filed a current report to note that it issued a press release with its financial results for the second quarter ended December 31, 2025. The press release is provided as Exhibit 99.1, and additional supplemental financial information is included as Exhibit 99.2.
The Clorox Company plans to acquire GOJO, maker of PURELL, by purchasing all of GOJO’s membership interests for $2.25 billion in cash, subject to customary adjustments and including anticipated tax benefits valued at approximately $330 million. Clorox expects to fund the deal primarily with debt financing, and completion will depend on regulatory approval and other customary closing conditions.
Alongside the transaction announcement, Clorox posted an investor presentation and issued a press release that reaffirms its fiscal 2026 outlook for net sales, diluted EPS and adjusted EPS. The company also outlines numerous risks and uncertainties that could affect the closing of the acquisition, integration of GOJO and the expected financial and strategic benefits.
The Clorox Company reported results of its virtual annual shareholder meeting held on November 19, 2025. Shareholders elected all company nominees to the board of directors, confirming the full slate of directors listed in the meeting materials.
Investors also approved, on an advisory basis, the compensation of Clorox’s named executive officers, indicating support for the company’s executive pay program. In addition, shareholders ratified the selection of Ernst & Young LLP as Clorox’s independent registered public accounting firm for the fiscal year ending June 30, 2026, allowing the firm to continue in its audit role.
The Clorox Company filed a Form 8-K to share its latest quarterly performance information. The company reported that it issued a press release detailing its financial results for the first quarter ended September 30, 2025, and made this document available as Exhibit 99.1.
The filing also includes supplemental financial information as Exhibit 99.2, offering additional detail on the quarter’s results. Together, these materials provide investors and analysts with a fuller picture of Clorox’s recent operating performance and financial condition.
The Clorox Company announced executive leadership changes. Eric Reynolds, Executive Vice President – Chief Operating and Strategy Officer, provided notice of his intention to resign after 27 years with the company. He will step down from his role effective December 2, 2025.
Reynolds will be available on an advisory basis as needed through February 2, 2026. The company stated it does not expect to appoint a replacement for Mr. Reynolds.